Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 967-982

  Jonsson B ^a   Strom O ^b,c   Eisman, J A ^d   Papaioannou, A ^e   Siris, E S ^f   Tosteson, A ^g   Kanis, J A ^h  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b i3 Innovus   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ST VINCENT S HOSPITAL   (Australia)

^e MCMASTER UNIVERSITY   (Canada)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adherence; Compliance; Fracture; Model; Persistence; Sweden

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; RISEDRONIC ACID; STRONTIUM RANELATE;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; ETIDRONIC ACID; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RANK LIGAND; THIOPHENES;

EID: 79951672053     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1424-x     Document Type: Article

References (76)

1. JA Kanis O Johnell 2005 Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 229 238 1:STN:280: DC%2BD2M%2Fps1Shtg%3D%3D 10.1007/s00198-004-1811-2 15618996 (Pubitemid 40379422)
2. PD Delmas 2002 Treatment of postmenopausal osteoporosis Lancet 359 2018 2026 1:CAS:528:DC%2BD38XksFKkt7g%3D 10.1016/S0140-6736(02)08827-X 12076571 (Pubitemid 34663722)
3. RK Murthy PK Morrow RL Theriault 2009 Bone biology and the role of the RANK ligand pathway Oncology (Williston Park) 23 9 15
4. SR Cummings J San Martin MR McClung ES Siris R Eastell IR Reid P Delmas HB Zoog M Austin A Wang S Kutilek S Adami J Zanchetta C Libanati S Siddhanti C Christiansen 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655
5. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023 (Pubitemid 44175011)
6. A Papaioannou G Ioannidis JD Adachi RJ Sebaldt N Ferko M Puglia J Brown A Tenenhouse WP Olszynski P Boulos DA Hanley R Josse TM Murray A Petrie CH Goldsmith 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database Osteoporos Int 14 808 813 1:CAS:528:DC%2BD3sXosFWrsLg%3D 10.1007/s00198-003-1431-2 14523610 (Pubitemid 37462130)
7. O Strom F Borgstrom JA Kanis B Jonsson 2009 Incorporating adherence into health economic modelling of osteoporosis Osteoporos Int 20 23 34 1:STN:280:DC%2BD1cjms1OksA%3D%3D 10.1007/s00198-008-0644-9 18521650
8. O Strom F Borgstrom SS Sen S Boonen P Haentjens O Johnell JA Kanis 2007 Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial Osteoporos Int 18 1047 1061 1:STN:280:DC%2BD2sznvV2nsA%3D%3D 10.1007/s00198-007-0349-5 17333449 (Pubitemid 47020004)
9. F Borgstrom B Jonsson O Strom JA Kanis 2006 An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials Osteoporos Int 17 1781 1793 1:STN:280:DC%2BD28nitVSktg%3D%3D 10.1007/s00198-006-0193-z 17009083 (Pubitemid 44607399)
10. JA Kanis J Adams F Borgstrom C Cooper B Jonsson D Preedy P Selby J Compston 2008 The cost-effectiveness of alendronate in the management of osteoporosis Bone 42 4 15 1:CAS:528:DC%2BD2sXhsVOrtrjL 10.1016/j.bone.2007.10. 019 18156107
11. Landfeldt E, Borgström F, Robbins S, Ström O (2009) A retrospective cohort study of medication adherence to treatment of osteoporosis in a Swedish population. Oral presentation, ISPOR, Paris
12. Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical Report, p61, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
13. Medical products agency (2007) Behandling av osteoporos. www.mpa.se
14. D Felsenberg A Silman M Lunt G Ambrecht A Ismail 2002 Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS) J Bone Miner Res 17 716 724 10.1359/jbmr.2002.17.4.716 (Pubitemid 34246648)
15. R Hasserius MK Karlsson BE Nilsson I Redlund-Johnell O Johnell 2003 Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study Osteoporos Int 14 61 68 1:STN:280:DC%2BD3s%2Fms1OqsA%3D%3D 10.1007/s00198-002- 1316-9 12577186 (Pubitemid 36267902)
16. NICE (2008) Systematic reviews of clinical effectiveness prepared for the guideline Osteoporosis: "Assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk". ( http://wwwniceorguk/guidance/indexjsp?action=byID&o=11621 )
17. Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or residronate: systematic reviews (NICE). The University of Sheffield, School of Health and Related Research ( http://www.nice.org.uk/guidance/index.jsp?action=download&o=36718 )
18. Stevenson M, Davis S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide. National Institute of Clinical Exelence (NICE), http://www.nice.org.uk/page.aspx?o=370643. Accessed 13 May 2009
19. JY Reginster O Bruyere A Sawicki A Roces-Varela P Fardellone A Roberts JP Devogelaer 2009 Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years Bone 45 1059 1064 1:CAS:528: DC%2BD1MXhtlGit7bE 10.1016/j.bone.2009.08.004 19679207
20. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 10.4065/82.12.1493 18053457 (Pubitemid 350211697)
21. McClung M, Freemantle N, Kendler D, Lillestol M, Moffett A, Satram-Hoang S, Yang Y, Kaur P, Macarios D, Siddhanti S (2010) Open-label study to evaluate the adherence, preference, and satisfaction of denosumab and alendronate in postmenopausal women. S 386 Osteoporos Int 21:[Suppl1]S25-S388 1 C P899
22. JA Kanis F Borgstrom O Johnell A Oden D Sykes B Jonsson 2005 Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study Osteoporos Int 16 15 25 1:STN:280:DC%2BD2M%2FksVentg%3D%3D 10.1007/s00198-004-1688-0 15672210 (Pubitemid 40193215)
23. JA Kanis O Johnell A Oden B Jonsson A Dawson W Dere 2000 Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden Osteoporos Int 11 120 127 1:STN:280:DC%2BD3c3lsVeguw%3D%3D 10.1007/PL00004173 10793869 (Pubitemid 30168796)
24. CE De Laet BA van Hout H Burger A Hofman HA Pols 1997 Bone density and risk of hip fracture in men and women: cross sectional analysis Br Med J 315 221 225 (Pubitemid 27326329)
25. O Johnell JA Kanis A Oden H Johansson C De Laet P Delmas JA Eisman S Fujiwara H Kroger D Mellstrom PJ Meunier LJ Melton 3rd T O'Neill H Pols J Reeve A Silman A Tenenhouse 2005 Predictive value of BMD for hip and other fractures J Bone Miner Res 20 1185 1194 10.1359/JBMR.050304 15940371 (Pubitemid 40863806)
26. CM Klotzbuecher PD Ross PB Landsman TA Abbott 3rd M Berger 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J Bone Miner Res 15 721 739 1:STN:280:DC%2BD3c3ktFOktA%3D%3D 10.1359/jbmr.2000.15.4.721 10780864 (Pubitemid 30174026)
27. Average Exchange Rates. http://www.riksbank.com Accessed 18 October 2009
28. Dental and Pharmaceutical Benefits Agency (2003) General guidelines for economic evaluations from the Pharmaceutical Benefits Board. www.tlv.se
29. F Borgstrom N Zethraeus O Johnell L Lidgren S Ponzer O Svensson P Abdon E Ornstein K Lunsjo KG Thorngren I Sernbo C Rehnberg B Jonsson 2006 Costs and quality of life associated with osteoporosis-related fractures in Sweden Osteoporos Int 17 637 650 10.1007/s00198-005-0015-8 16283064
30. O Ström F Borgstrom N Zethraeus O Johnell L Lidgren S Ponzer O Svensson P Abdon E Ornstein L Ceder KG Thorngren I Sernbo B Jonsson 2008 Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden Acta Orthop 79 269 280 10.1080/17453670710015094 18484255 (Pubitemid 351878360)
31. JA Kanis A Oden O Johnell B Jonsson C de Laet A Dawson 2001 The burden of osteoporotic fractures: a method for setting intervention thresholds Osteoporos Int 12 417 427 1:STN:280:DC%2BD3MzovF2gtw%3D%3D 10.1007/s001980170112 11444092 (Pubitemid 32606468)
32. JA Kanis O Johnell A Oden I Sembo I Redlund-Johnell A Dawson C De Laet B Jonsson 2000 Long-term risk of osteoporotic fracture in Malmo Osteoporos Int 11 669 674 1:STN:280:DC%2BD3M%2FlsFarsw%3D%3D 10.1007/s001980070064 11095169
33. B Jonsson C Christiansen O Johnell J Hedbrandt 1995 Cost-effectiveness of fracture prevention in established osteoporosis Osteoporos Int 5 136 142 1:STN:280:DyaK2Mzit1Olsg%3D%3D 10.1007/BF01623315 7599450
34. Ekman M (2002) Consumption and production by age in Sweden: Basic facts and health economic implications. http://www.tlv.se/Upload/Foretag/FOR-040506- tabell-lakemedel.pdf, Accessed 2009-12-11
35. Johanesson M, Jonsson B, Jonsson L, Kobelt G, Zethraeus N (2009) Why should economic evaluations of medical innovations have a societal perspective? Office of healt economics (OHE) No. 51 October
36. K Burstrom M Johannesson F Diderichsen 2001 Swedish population health-related quality of life results using the EQ-5D Qual Life Res 10 621 635 1:STN:280:DC%2BD38%2Fptlyhuw%3D%3D 10.1023/A:1013171831202 11822795 (Pubitemid 34056332)
37. P Dolan 1997 Modeling valuations for EuroQol health states Med Care 35 1095 1108 1:STN:280:DyaK1c%2FjtlKrtg%3D%3D 10.1097/00005650-199711000-00002 9366889 (Pubitemid 127453463)
38. Statistics Sweden http://www.ssd.scb.se/databaser/makro/Produkt.asp? produktid=BE0101, Accessed 2010-03-16
39. The National Board of Health and Welfare. National Patient Register (NPC) and Cause of Death Register (CDR). http://www.sos.se/epc/epceng.htm
40. G Ioannidis A Papaioannou WM Hopman N Akhtar-Danesh T Anastassiades L Pickard CC Kennedy JC Prior WP Olszynski KS Davison D Goltzman L Thabane A Gafni EA Papadimitropoulos JP Brown RG Josse DA Hanley JD Adachi 2009 Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study Cmaj 181 265 271 19654194
41. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882 1:STN:280:DyaK1M7ptFOlug%3D%3D 10.1016/S0140-6736(98)09075-8 10093980 (Pubitemid 29126875)
42. O Johnell JA Kanis A Oden I Sernbo I Redlund-Johnell C Petterson C De Laet B Jonsson 2004 Mortality after osteoporotic fractures Osteoporos Int 15 38 42 1:STN:280:DC%2BD2c%2FitlOhsw%3D%3D 10.1007/s00198-003-1490-4 14593451 (Pubitemid 38252438)
43. JA Barrett JA Baron ML Beach 2003 Mortality and pulmonary embolism after fracture in the elderly Osteoporos Int 14 889 894 10.1007/s00198-003-1494-0 12942231 (Pubitemid 38009528)
44. JA Kanis A Oden O Johnell C De Laet B Jonsson 2004 Excess mortality after hospitalisation for vertebral fracture Osteoporos Int 15 108 112 10.1007/s00198-003-1516-y 14598026 (Pubitemid 38252423)
45. D Bliuc ND Nguyen VE Milch TV Nguyen JA Eisman JR Center 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women Jama 301 513 521 1:CAS:528:DC%2BD1MXhtlyqs7Y%3D 10.1001/jama.2009.50 19190316
46. JA Kanis A Oden O Johnell C De Laet B Jonsson AK Oglesby 2003 The components of excess mortality after hip fracture Bone 32 468 473 1:STN:280:DC%2BD3s3jtVGhtg%3D%3D 10.1016/S8756-3282(03)00061-9 12753862 (Pubitemid 39665705)
47. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial Jama 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 10.1001/jama.280.24.2077 9875874 (Pubitemid 29014065)
48. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
49. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier JY Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 10.1056/NEJM200102013440503 11172164 (Pubitemid 32107641)
50. EV McCloskey H Johansson A Oden S Vasireddy K Kayan K Pande T Jalava JA Kanis 2009 Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811 817 1:CAS:528:DC%2BD1MXjvFaqt78%3D 10.1007/s00198-008-0786-9 19002369
51. JA Kanis H Johansson A Oden EV McCloskey 2009 Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049 1054 1:CAS:528:DC%2BD1MXlslWisrw%3D 10.1016/j.bone.2009. 02.014 19254788
52. Vägverket (1997) Vägverkets samhällsekonomiska kalkymodell. Ekonomisk teori och värderingar. In Authority VSR (ed). Stockholm
53. AN Tosteson RT Burge DA Marshall R Lindsay 2008 Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations Am J Manag Care 14 605 615 18778176
54. Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW (2010) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int (E-pub ahead of print)
55. JA Kanis M Stevenson EV McCloskey S Davis M Lloyd-Jones 2007 Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Health Technol Assess 11 1 256
56. Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide( http://guidance.nice.org.uk/page.aspx?o=370643 )
57. Ström O, Landfeldt E, Robbins S, Borgström F (2010) Adherence to treatment of osteoporosis and fracture risk: The Swedish Adherence Register Analysis (SARA). Oral presentation/poster ECCEO/IOF, Florence
58. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
59. E McCloskey D De Takats J Orgee S Aropinn T Jalava J Cliffe L Reaney C McGurk DJAK Charlesworth 2005 Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community based clinical trial J Bone Miner Res 20 suppl 1 S282
60. B Jonsson J Kanis A Dawson A Oden O Johnell 1999 Effect and offset of effect of treatments for hip fracture on health outcomes Osteoporos Int 10 193 199 1:STN:280:DC%2BD3c7ht1KrtA%3D%3D 10.1007/s001980050215 10525710 (Pubitemid 29458713)
61. JA Kanis B Jonsson 2002 Economic evaluation of interventions for osteoporosis Osteoporos Int 13 765 767 1:STN:280:DC%2BD38nitFSmsw%3D%3D 10.1007/s001980200106 12378364 (Pubitemid 36336720)
62. JA Kanis F Borgstrom O Johnell B Jonsson 2004 Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women Osteoporos Int 15 862 871 1:STN:280:DC%2BD2crhvFWktQ%3D%3D 10.1007/s00198-004-1643-0 15175846 (Pubitemid 39506452)
63. WHO (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneve. http://whqlibdoc.who.int/publications/1998/9241545224-eng. pdf, Accessed
64. R Prince A Sipos A Hossain U Syversen S Ish-Shalom E Marcinowska J Halse R Lindsay GP Dalsky BH Mitlak 2005 Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment J Bone Miner Res 20 1507 1513 1:CAS:528:DC%2BD2MXhtVOltrrN 10.1359/JBMR.050501 16059622 (Pubitemid 41243539)
65. GA Greendale M Espeland S Slone R Marcus E Barrett-Connor 2002 Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study Arch Intern Med 162 665 672 1:CAS:528:DC%2BD38XivVyhtbc%3D 10.1001/archinte.162.6.665 11911720 (Pubitemid 34226393)
66. YZ Bagger LB Tanko P Alexandersen HB Hansen A Mollgaard P Ravn P Qvist JA Kanis C Christiansen 2004 Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study Bone 34 728 735 1:CAS:528:DC%2BD2cXisF2ntb0%3D 10.1016/j.bone.2003.12.021 15050905 (Pubitemid 38393810)
67. C Christiansen MS Christensen I Transbol 1981 Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy Lancet 1 459 461 1:CAS:528:DyaL3MXktVWjtr8%3D 10.1016/S0140-6736(81)91848-1 6110089 (Pubitemid 11130971)
68. JA Cauley DG Seeley K Ensrud B Ettinger D Black SR Cummings 1995 Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group Ann Intern Med 122 9 16 1:STN:280: DyaK2M%2Fnslagtw%3D%3D 7985914
69. E Banks V Beral G Reeves A Balkwill I Barnes 2004 Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women Jama 291 2212 2220 1:CAS:528:DC%2BD2cXktVGitbc%3D 10.1001/jama.291.18.2212 15138243 (Pubitemid 38608170)
70. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial Jama 296 2927 2938 1:CAS:528:DC%2BD2sXnvVGh 10.1001/jama.296.24.2927 17190893 (Pubitemid 46021497)
71. AM Gallagher S Rietbrock M Olson TP van Staa 2008 Fracture outcomes related to persistence and compliance with oral bisphosphonates J Bone Miner Res 23 1569 1575 10.1359/jbmr.080510 18505366
72. JR Curtis AO Westfall H Cheng E Delzell KG Saag 2008 Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday Osteoporos Int 19 1613 1620 1:STN:280:DC%2BD1cnksVCrsA%3D%3D 10.1007/s00198-008-0604-4 18483689
73. I Lekander F Borgstrom O Strom N Zethraeus JA Kanis 2008 Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK-Results based on the Women's Health Initiative randomised controlled trial Bone 42 294 306 1:CAS:528:DC%2BD1cXls1egsQ%3D%3D 10.1016/j.bone.2007.09.059 18053789
74. N Zethraeus F Borgstrom B Jonsson J Kanis 2005 Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial Int J Technol Assess Health Care 21 433 441 10.1017/S0266462305050609 16262965 (Pubitemid 41642834)
75. NICE (2008) Osteoporosis-secondary prevention including strontium ranelate: Appraisal consultation document. www.nice.org.uk
76. F Borgstrom O Johnell JA Kanis A Oden D Sykes B Jonsson 2004 Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Pharmacoeconomics 22 1153 1165 10.2165/00019053-200422170-00005 15612833 (Pubitemid 39665345)